CSL Limited
45 Poplar Road Parkville
Victoria 3052 Australia

T +613 9389 1911
F +613 9389 1434
www.csl.com.au

ASX Announcement

For immediate release

22 February 2012

Interim Result
Reported profit $483 million, down 3%
- ***Up 16% at constant currency[1]***
- ***Foreign currency headwind of $95m***

Earnings per share 92.2 cents, up 1%
Cash flow from operations of $522 million, up 28%
Full year profit guidance upgraded
- ***Approximately 13% growth at constant currency***

Buyback 20% complete
Dividend increased to 36 cents per share

CSL Limited (ASX:CSL) today announced a net profit after tax of $483 million for the six months ended 31 December 2011, down $17 million or 3% on a reported basis when compared to the prior comparable period. This result included an unfavourable foreign exchange impact of $95 million. On a constant currency[1] basis, net profit after tax grew 16%. Earnings per share benefited from current and past capital management initiatives.

KEY ITEMS

Financial

- Sales revenue $2.2 billion, up 13% at constant currency when compared to the prior comparable period
  - *CSL Behring sales US$1.9 billion, up 17%*
- Reported net profit after tax $483 million, down 3%
  - *Up 16% at constant currency[1]*
  - *Foreign currency headwind of $95 million*
- Reported earnings per share 92.2 cents, up 1%
- Research and development expenditure of $161 million up 16% at constant currency
- Cash flow from operations of $522 million, up 28%
- Strong balance sheet, cash on hand $1,300 million, borrowings $1,278 million
- $900m on market share buyback approximately 20% complete, $181 million spent
- Interim dividend increased to 36 cents per share, unfranked, payable on 13 April 2012.

[1] Constant currency removes the impact of exchange rate movements to facilitate comparability. See end note # for further detail.

Operational

- Immunoglobulin sales up 21% at constant currency
  - Strong demand across the product range
  - Privigen® – European phase III study in CIDP completed
- Specialty products up 20% at constant currency
  - RiaSTAP™ – phase III peri-operative bleeding study initiated in Europe
  - Berinert® - US and European approval for self administration
- Recombinant haemophilia pipeline
  - rIX-FP - commencement of phase II/III pivotal study
  - rVIIa – US FDA grants orphan drug designation
  - rVIII-SingleChain – first patient recruited for trial
- GARDASIL*
  - Recommended for vaccinating boys in Australia, Canada & USA
- Investment in facilities expansion
- Capital Management
  - ~$800m in new lines of credit
  - US$750m private placement
  - Buyback 20% complete

Dr Brian McNamee, CSL's Managing Director, said "We've delivered a strong performance across the portfolio, albeit somewhat masked by ongoing currency headwinds. Cash flow exceeded profit and together with a US$750 million US private placement underpins the funding for the current buyback program, which is now 20% complete."

"Demand for our immunoglobulin products Privigen®, Hizentra® as well as our lyophilised product, Carimune®, has been vigorous, despite economic pressures in Europe and the US," Dr McNamee said.

OUTLOOK *(at 10/11 exchange rates)*

Commenting on CSL's outlook, Dr McNamee said "CSL is well placed for continued growth with an excellent portfolio of products and a broad geographic sales reach. I'm pleased to be able to upgrade our guidance of ~10% profit growth provided at the Annual General Meeting in October last year.

We now anticipate profit will grow approximately 13%, using fiscal 2011 exchange rates, to around $1,060 million, despite continuing economic pressures in Europe and the US and the return of a competitor to the market. Growth in earnings per share at constant currency will exceed this as shareholders benefit from the effect of the share buyback," Dr McNamee said.

In compiling the Company's financial forecasts for the year ending 30 June 2012 a number of key variables which may have a significant impact on guidance have been identified and these have been included in the footnote[2] below. To assist investors in determining the impact of movement in key currency pairs, we have provided with our results materials a foreign currency sensitivity analysis. The materials have also been posted on the Company's website www.csl.com.au.

Provided at the end of this release is a restatement of the Group's results in US dollars. US dollars are the pharmaceutical industry standard currency for reporting purposes and the restatement is provided to assist investors in their evaluation of the Company's results. It also reflects the increasing predominance of the Company's sales worldwide in US dollars. Consistent with this industry standard, the Company intends to move to reporting in US dollars commencing with the 2012/13 financial year.

BUSINESS REVIEW
Results overview

CSL Behring sales of US$1.9 billion grew 17%, or 13% on a constant currency basis when compared to the prior comparable period.

Immunoglobulins grew 21% in constant currency terms. Demand growth for all presentations of immunoglobulin, particularly Privigen®, was strong. Geographically, demand growth was across all key markets but particularly strong in Europe. The absence of a competitor from the market place and a product mix shift in demand towards subcutaneous immunoglobulin Hizentra® contributed to this growth.

---

[2] Key variables which may have a significant impact on guidance include material price and volume movements on core plasma products, competitor activity, changes in healthcare regulations and reimbursement policies, royalties arising from the sale of Human Papillomavirus vaccine, internationalisation of the Company's influenza vaccine sales and plasma therapy life cycle management strategies, enforcement of key intellectual property, regulatory risk, litigation, the effective tax rate and foreign exchange movements.

Albumin, including Asian sales[3], grew 14% in constant currency terms underpinned by ongoing demand in China.

Haemophilia product sales grew 4% in constant currency terms. Demand for immune tolerance therapy treatment in Europe and for Beriate® in emerging markets drove this growth. Typically, however, these sales are in new lower priced markets.

Specialty products grew 20% in constant currency terms. The changing paradigm for the treatment of peri-operative bleeding has seen solid growth in demand for Haemocomplettan® in Europe. Berinert® growth received a boost in sales following approvals in both the US and Europe for self administration.

Other Human Health (CSL Biotherapies) sales of $417 million included $65 million of albumin sales into Asia. Excluding these sales, this segment grew 13% on a constant currency basis when compared to the prior comparable period.

Plasma therapy sales from the Broadmeadows plant contributed $125 million. Influenza sales of $93 million were boosted by solid sales into northern hemisphere markets. Gardasil* sales growth into the Australian National Immunisation Program and private markets also contributed to this result.

Intellectual Property Licensing revenue was $80 million. Royalty contributions from Human Papillomavirus Vaccines totalled $61 million and the sale of intellectual property associated with enzyme replacement treatment for Mucopolysaccharidosis contributed $18 million to revenue.

BUSINESS DEVELOPMENT

Immunoglobulins

During January 2012, CSL Behring concluded its phase III trial studying the use of Privigen® in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). Trial results are currently being drawn together for the registration submission in Europe planned for the first half of calendar 2012.

[3] Adjusted to include CSL Behring albumin products sold in Asia by CSL Biotherapies.

Haemophilia

CSL and CSL Behring are working on a number of innovative recombinant factors for the treatment of Haemophilia.

Recombinant IX-FP

On 12 January 2012, CSL Behring announced that the first site (located in Vienna) has been initiated in its global phase II/III multi-centre study to evaluate the safety, efficacy and pharmacokinetics of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP).

On 2 February 2012, CSL Behring announced results of a phase I study evaluating recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in patients with severe haemophilia B. Results of the study showed the rIX-FP was well tolerated with no serious adverse events, no presence of inhibitors to Factor IX, or antibodies to rIX-FP were reported. Terminal half-life (a measure of how long the drug lasts in the body) was more than five times longer in comparison to values associated with current recombinant FIX therapy.

Recombinant VIIa-FP

On 16 February 2012, CSL Behring announced that it had been granted orphan drug designation by the US Food and Drug Administration for its novel recombinant fusion protein linking activated coagulation factor VIIa with recombinant albumin (rVIIa-FP). The Orphan Drug Designation was granted for the treatment and prophylaxis of bleeding episodes in patients with congenital haemophilia and inhibitors to coagulation factor VIII or IX.

Recombinant VIII-SingleChain

CSL627, the candidate molecule being studied for the treatment of haemophilia A, is a unique single chain recombinant factor VIII (rVIII-SingleChain). On 15 February 2012, CSL Behring screened the first patient for its rVIII-SingleChain phase I trial.

In house studies have shown that the molecular integrity of CSL627 is significantly increased using the single chain design, resulting in a homogenous product that may be more stable than currently available options. In addition, in-vitro studies have shown that CSL627 demonstrates a very strong affinity for von Willebrand factor (VWF) and a faster and more efficient binding to VWF. The factor VIII/VWF complex plays an important role in the physiological activity and clearance of factor VIII and has been shown to have an influence on the presentation of factor VIII to the immune system.

Specialty Plasma Products

Berinert® (C1-Esterase Inhibitor)

On 25 August 2011, CSL Behring announced that European health authorities approved self administration of Berinert®, a C1-esterase inhibitor concentrate indicated in Europe for the treatment of acute attacks of hereditary angioedema (HAE), a rare, serious and sometimes life threatening genetic disorder. The expanded European label allows patients to self administer Berinert® by intravenous infusion, after consultation with a physician and after receiving the appropriate training. Berinert® is licensed in Europe for treatment of acute HAE attacks.

On 3 January 2012, CSL Behring announced US Food and Drug Administration (FDA) approval of a label expansion for self-administration of Berinert®, C1 esterase inhibitor (Human) for the treatment of acute attacks of HAE. With appropriate training from a physician, patients in the US can now self-administer Berinert® by intravenous infusion. As part of the US label expansion, Berinert® is now also indicated to treat life-threatening laryngeal HAE attacks, as well as facial and abdominal attacks.

RiaSTAP™

During January 2012, CSL Behring enrolled the first patient in a phase III peri-operative bleeding study. RiaSTAP® is approved in the US for treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency.

CAM3001

During the period under review, CSL's antibody licensee AstraZeneca successfully completed a phase IIa study of a monoclonal antibody targeting the GM-CSF Receptor for the potential treatment of Rheumatoid Arthritis. Mavrilimumab* showed a rapid and significant clinical effect compared to placebo with a safety profile supporting further clinical development.

CORPORATE RESPONSBILITY

Cytogam®

On 8 December 2011, CSL announced that it is partnering with the world's largest health research agency, the US National Institute of Health (NIH), to study a potential new treatment for the prevention of congenital cytomegalovirus (CMV) infection, one of the most common known causes of congenital abnormalities in the developed world.

CSL, through its Swiss subsidiary, CSL Behring AG, is donating Cytogam® to the NIH for the use in this trial as part of its commitment to addressing significant public health issues through collaborative research.

Cytogam® is an intravenous immune globulin enriched in antibodies against cytomegalovirus. It is used to prevent infection against CMV disease associated with transplantation of the kidney, liver, pancreas and heart. CMV is the most common cause of infection occurring after any solid organ transplant, contributing significantly to morbidity and mortality in organ transplant recipients.

Corporate Responsibility Report
On 13 December 2011, CSL released its third Corporate Responsibility Report, providing a comprehensive account of the Company's economic, social and environmental performance in 2010/11. The report is available on the company's website at www.csl.com.au.

CAPITAL MANAGEMENT

Debt Refinancing
On 9 November CSL announced that it had completed a debt refinancing program which included:

- A US$750 million private placement in the US; and
- The equivalent of approximately $800 million in new lines of credit with its banks

The new funds will be used to repay existing debt, fund CSL's capital management plan, including the on-market share buyback of up to $900 million announced at the Annual General Meeting, and for general corporate purposes.

Share Buyback
On 19 October 2011, CSL announced its intention to conduct an on-market share buyback of up to $900 million. Under the Australian Securities Exchange listing rules this buyback has a 12 month completion window. To date CSL has repurchased 5.8 million shares for approximately $181 million, representing ~20% of the intended repurchase program.

CSL's balance sheet remains very sound. Cash and cash equivalents totalled $1,300 million as at 31 December 2011, with interest bearing liabilities totalling $1,278 million. Undrawn debt facilities totalled $450 million.

Additional details about CSL's results are included in the Company's 4D statement, Investor Presentation slides and webcast, all of which can be found on the Company's website www.csl.com.au

For further information, please contact:

Media:
Sharon McHale
Senior Director Public Affairs
CSL Limited
Phone: +613 9389 1506
Mobile +614 0997 8314
Email: sharon.mchale@csl.com.au

Tim Duncan
Hintons & Associates
Phone: +613 9600 1979
Mobile: +614 0844 1122
Email: tduncan@hintons.com.au

Investors:
Mark Dehring
Head of Investor Relations
CSL Limited
Telephone: +613 9389 2818
Email: mark.dehring@csl.com.au

Group Results

Australian Dollars

Six months ended December $ Millions	**Dec 2010** Reported	**Dec 2011** Reported	**Dec 2011** Constant Currency#	**Change** %[4]
Sales	**2,116**	**2,221**	**2,401**	**13.4%**
Other Revenue / Income	56	88	95	
Total Revenue / Income	**2,172**	**2,309**	**2,496**	
Earnings before Interest, Tax, Depreciation & Amortisation	**719**	**689**	**811**	**12.9%**
Depreciation/Amortisation	83	82	85	
Earnings before Interest and Tax	**636**	**607**	**726**	**14.2%**
Net Interest Expense / (Income)	(11)		1	
Tax Expense	147	124	148	
Net Profit after Tax	**500**	**483**	**578**	**15.5%**
Interim Dividends (cents)	35.00	36.00		
Basic EPS (cents)	91.5	92.2		

[4] Change between Dec 2011 results at constant currency and Dec 2010 reported results.

Group Results

***Restated in US Dollars*[5]**

Six months ended Dec US$ Millions	**Dec 2010** Reported	**Dec 2011** Reported	**Change** %[6]
Sales	**1,956**	**2,324**	**18.8%**
Other Revenue / Income	52	91	
Total Revenue / Income	**2,008**	**2,414**	
Earnings before Interest, Tax, Depreciation & Amortisation	**664**	**720**	**8.4%**
Depreciation/Amortisation	76	86	
Earnings before Interest and Tax	**588**	**634**	**7.8%**
Net Interest Expense / (Income)	(10)		
Tax Expense	135	130	
Net Profit after Tax	**463**	**504**	**8.9%**

[5] The Group's result in USD has been prepared by translating the results of all entities in the Group into US dollars using average exchange rates. Accounting policies used in the preparation of the Group's financial statements have been consistently applied in this process.

[6] Change between Dec 2011 reported results and Dec 2010 reported results.

#***Constant currency*** *removes the impact of exchange rate movements to facilitate comparability by restating the current year's results at the prior year's rates. This is done in two parts: a) by converting the current year net profit of entities in the group that have reporting currencies other than Australian Dollars at the rates that were applicable to the prior year ("translation currency effect") and comparing this with the actual profit of those entities for the current year; and b) by restating material transactions booked by the group that are impacted by exchange rate movements at the rate that would have applied to the transaction if it had occurred in the prior year ("transaction currency effect") and comparing this with the actual transaction recorded in the current year. The sum of translation currency effect and transaction currency effect is the amount by which reported net profit is adjusted to calculate the result at constant currency.*

Summary

Reported Net Profit after Tax	*$483.3m*
Translation Currency Effect (a)	*$ 4.1m*
Transaction Currency Effect (b)	*$ 90.6m*
*Constant currency Net Profit after Tax **	*$578.0m*

a. Translation Currency Effect $4.1m

Average Exchange rates used for calculation in major currencies were as follows:

	Six months to	
	Dec 11	*Dec 10*
AUD/USD	*1.05*	*0.93*
AUD/EUR	*0.75*	*0.71*
AUD/CHF	*0.89*	*0.94*

b. Transaction Currency Effect $90.6m

Transaction currency effect is calculated by reference to the applicable prior year exchange rates. The calculation takes into account the timing of sales both internally within the CSL Group (ie from a manufacturer to a distributor) and externally (ie to the final customer) and the relevant exchange rates applicable to each transaction.

** Constant currency Net profit after Tax has not been audited or reviewed in accordance with Australian Auditing Standards*